Laquinimod

Phase 3Small molecule

Teva

Laquinimod is one of 112 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Relapsing-Remitting Multiple SclerosisActive, not recruiting

Primary Progressive Multiple SclerosisActive, not recruiting

Multiple SclerosisActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 3

Active, not recruiting

Primary Progressive Multiple SclerosisPhase 2

Active, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Laquinimod

Teva

Phase 3

4 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Avonex

EMD Serono

Preclinical

22 6

Campath

GGenzyme, a Sanofi Company

Preclinical

12 7

Zinbryta

Roche

Preclinical

2 8

Flomax

Sanofi

Preclinical

1 9

Myfortic

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis4 trials

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Completed· Teva logo

Teva·Phase 3·NCT00509145·1,106 enrolled

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Terminated· Teva logo

Teva·Phase 3·NCT01047319·1,047 enrolled

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Completed· Teva logo

Teva·Phase 3·NCT01707992·2,199 enrolled

Show 1 more trial

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Withdrawn· Teva logo

Teva·Phase 3·NCT01975298

Systemic Lupus Erythematosus2 trials

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Completed· Teva logo

Teva·Phase 2·NCT01085084·82 enrolled

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

Completed· Teva logo

Teva·Phase 2·NCT01085097·46 enrolled

Double-blind1 trial

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Withdrawn· Teva logo

Teva·Phase 2·NCT01404117

Effectiveness1 trial

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Completed· Teva logo

Teva·Phase 2·NCT00349193·306 enrolled

Treatment1 trial

A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together

Completed· Teva logo

Teva·Phase 1·NCT02085863·40 enrolled

6 more indications

Huntington's Disease (HD)1 trial

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

Completed· Teva logo

Teva·Phase 2·NCT02215616·352 enrolled

Primary Progressive Multiple Sclerosis1 trial

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Completed· Teva logo

Teva·Phase 2·NCT02284568·374 enrolled

Crohn's Disease1 trial

Laquinimod Phase IIa Study in Active Crohn's Disease

Completed· Teva logo

Teva·Phase 2·NCT00737932·180 enrolled

ART1 trial

A Study of Laquinimod Eye-drops in Healthy Participants

Completed·AActive Biotech AB·Phase 1·NCT05187403·54 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Completed· Teva logo

Teva·Phase 3·NCT00605215·1,331 enrolled

Unspecified2 trials

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Terminated· Teva logo

Teva·Phase 2·NCT00745615·257 enrolled

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Terminated· Teva logo

Teva·Phase 3·NCT00988052·839 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Laquinimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Laquinimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Laquinimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Teva

Laquinimod

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis4 trials

Systemic Lupus Erythematosus2 trials

Double-blind1 trial

Effectiveness1 trial

Treatment1 trial

Huntington's Disease (HD)1 trial

Primary Progressive Multiple Sclerosis1 trial

Crohn's Disease1 trial

ART1 trial

Relapsing-Remitting Multiple Sclerosis1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News